Literature DB >> 18297166

Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets.

Anthony Nardone1, Annedore Tischer, Nick Andrews, Jo Backhouse, Heidi Theeten, Nina Gatcheva, Marios Zarvou, Bohumir Kriz, Richard G Pebody, Kalman Bartha, Darina O'Flanagan, Dani Cohen, Arnis Duks, Algirdas Griskevicius, Joel Mossong, Christopher Barbara, Adrianna Pistol, Margareta Slaciková, Katarina Prosenc, Kari Johansen, Elizabeth Miller.   

Abstract

OBJECTIVE: To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets.
METHODS: Between 1996 and 2004, representative serum banks were established in 17 countries by collecting residual sera or community sampling. Serum banks were tested in each country and assay results were standardized. With a questionnaire, we collected information on current and past rubella vaccination programmes in each country. The percentage of seronegative (< 4 IU/ml) children (2-14 years of age) was used to evaluate rubella susceptibility, and countries were classified by seronegativity as group I (< 5%), group II (5-10%) or group III (> 10%). The proportion of women of childbearing age without rubella protection (< or = 10 IU/ml) was calculated and compared with WHO targets of < 5%.
FINDINGS: Only Romania had no rubella immunization programme at the time of the survey; the remaining countries had a two-dose childhood schedule using the measles, mumps and rubella (MMR) vaccine. The percentage of susceptible children defined five countries as group I, seven as group II and four as group III. Women of childbearing age without rubella protection were < 5% in only five countries.
CONCLUSION: Despite the low reported incidence in many countries, strengthening the coverage of the routine two-dose of MMR vaccine among children is needed, especially in group III countries. Catch-up campaigns in older age groups and selective targeting of older females are needed in many countries to ensure necessary levels of protective immunity among women of childbearing age.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297166      PMCID: PMC2647372          DOI: 10.2471/blt.07.042010

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  28 in total

1.  Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2).

Authors:  A Nardone; E Miller
Journal:  Euro Surveill       Date:  2004-04

2.  Rubella outbreak in an unvaccinated religious community in the Netherlands leads to cases of congenital rubella syndrome.

Authors:  Ytje van der Veen; Susan Hahné; Helma Ruijs; Rob van Binnendijk; Aura Timen; A M van Loon; Hester de Melker
Journal:  Euro Surveill       Date:  2005-11-24

3.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

Review 4.  Rubella in Europe.

Authors:  A Galazka
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

5.  Towards elimination: measles susceptibility in Australia and 17 European countries.

Authors:  Nick Andrews; Annedore Tischer; Annette Siedler; Richard G Pebody; Christopher Barbara; Suzanne Cotter; Arnis Duks; Nina Gacheva; Kriz Bohumir; Kari Johansen; Joel Mossong; Fernando de Ory; Katarina Prosenc; Margareta Sláciková; Heidi Theeten; Marios Zarvou; Adriana Pistol; Kalman Bartha; Dani Cohen; Jo Backhouse; Algirdas Griskevicius
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

Review 6.  Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.

Authors:  T Panagiotopoulos; I Antoniadou; E Valassi-Adam
Journal:  BMJ       Date:  1999-12-04

7.  Vaccination against rubella and measles: quantitative investigations of different policies.

Authors:  R M Anderson; R M May
Journal:  J Hyg (Lond)       Date:  1983-04

8.  The seroepidemiology of rubella in western Europe.

Authors:  R G Pebody; W J Edmunds; M Conyn-van Spaendonck; P Olin; G Berbers; I Rebiere; H Lecoeur; P Crovari; I Davidkin; G Gabutti; E Gerike; C Giordano; L Hesketh; A M Plesner; M Raux; M C Rota; S Salmaso; A Tischer; M Valle; E Miller
Journal:  Epidemiol Infect       Date:  2000-10       Impact factor: 2.451

9.  Preventing congenital rubella infection in the European Region of WHO: 2010 target.

Authors:  J S Spika; F X Hanon; S Wassilak; R Pebody; N Emiroglu
Journal:  Euro Surveill       Date:  2004-04

10.  Selective immunization: protection of the individual.

Authors:  J A Dudgeon
Journal:  Rev Infect Dis       Date:  1985 Mar-Apr
View more
  23 in total

1.  Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA 27/3 in junior high school.

Authors:  Ching-Chiang Lin; Chun-Yuh Yang; Yung-Luen Shih; Yang-Yang Huang; Tsung-Han Yang; Jin-Yuan Liang; Chu-Fen Chang; Hsiu-Shu Hsieh; Yeou-Lih Huang
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  Towards elimination: measles susceptibility in Australia and 17 European countries.

Authors:  Nick Andrews; Annedore Tischer; Annette Siedler; Richard G Pebody; Christopher Barbara; Suzanne Cotter; Arnis Duks; Nina Gacheva; Kriz Bohumir; Kari Johansen; Joel Mossong; Fernando de Ory; Katarina Prosenc; Margareta Sláciková; Heidi Theeten; Marios Zarvou; Adriana Pistol; Kalman Bartha; Dani Cohen; Jo Backhouse; Algirdas Griskevicius
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

3.  Response to third rubella vaccine dose.

Authors:  Lotta Siira; Hanne Nøkleby; Regine Barlinn; Øystein R Riise; Ingeborg S Aaberge; Susanne G Dudman
Journal:  Hum Vaccin Immunother       Date:  2018-06-21       Impact factor: 3.452

4.  Sero-prevalence of rubella among pregnant women in Sub-Saharan Africa: a meta-analysis.

Authors:  Zemenu Yohannes Kassa; Siraj Hussen; Solomon Asnake
Journal:  Hum Vaccin Immunother       Date:  2020-03-20       Impact factor: 3.452

5.  Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain.

Authors:  Alba González-Escalada; Laura García-García; Pablo Viguera-Ester; Patricia Marín-García; Jesus García; Angel Gil-de-Miguel; Ruth Gil-Prieto
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

Review 6.  Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome.

Authors:  Megan K Young; Allan W Cripps; Graeme R Nimmo; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2015-09-09

7.  Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?

Authors:  J Eriksen; I Davidkin; G Kafatos; N Andrews; C Barbara; D Cohen; A Duks; A Griskevicius; K Johansen; K Bartha; B Kriz; G Mitis; J Mossong; A Nardone; D O'Flanagan; F DE Ory; A Pistol; H Theeten; K Prosenc; M Slacikova; R Pebody
Journal:  Epidemiol Infect       Date:  2012-06-12       Impact factor: 4.434

8.  Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.

Authors:  L W Ang; F Y Lai; S H Tey; J Cutter; L James; K T Goh
Journal:  Epidemiol Infect       Date:  2012-09-24       Impact factor: 4.434

9.  Rubella seroprevalence among primary and pre- primary school pupils at Moi's Bridge location, Uasin Gishu District, Kenya.

Authors:  Janeth J Kombich; Paul C Muchai; Peter Tukei; Peter K Borus
Journal:  BMC Public Health       Date:  2009-07-29       Impact factor: 3.295

10.  How useful is a history of rubella vaccination for determination of disease susceptibility? A cross-sectional study at a public funded health clinic in Malaysia.

Authors:  Ai Theng Cheong; Seng Fah Tong; Ee Ming Khoo
Journal:  BMC Fam Pract       Date:  2013-01-31       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.